Maze Therapeutics doses first subject in Phase II AKD treatment trial
Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) inhibitor, …
Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) inhibitor, …
Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes …
Sepsis is a life-threatening condition that occurs when the body’s response to infection causes widespread inflammation that damages its tissues …
Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) …
A Phase I trial of Replicate Bioscience’s self-replicating RNA-based vaccine for rabies has elicited an immune response against a disease …
A Phase I trial of Replicate Bioscience’s self-replicating RNA-based vaccine for rabies has elicited an immune response against a disease …
Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised …
The 43rd Annual JP Morgan Healthcare Conference took place in San Francisco, California on January 13–16, 2025. This annual conference is …
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company …
Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 receptor (MC4R) bremelanotide with …
AI has frequently been in the headlines recently due to its potentially transformative capabilities — and the technology is making …
The US Military’s Defence Health Agency (DHA) has partnered with the Global Coalition for Adaptive Research (GCAR) for a platform …
MSD has commenced the Phase III waveLINE-010 trial to assess its investigational antibody-drug conjugate (ADC), zilovertamab vedotin, combined with rituximab …
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential …
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III …